[ad_1]
Vos, M. B., Kimmons, J. E., Gillespie, C., Welsh, J. & Blank, H. M. Dietary fructose consumption among US children and adults: The Third National Health and Nutrition Examination Survey CME. Medscape Gen. Med. 10, 160 (2008).
Nakagawa, T. et al. Fructose contributes to the Warburg effect for cancer growth. Cancer Metab. 8, 16 (2020).
Kanarek, N., Petrova, B. & Sabatini, D. M. Dietary modifications for enhanced cancer therapy. Nature 579, 507–517 (2020).
Jeong, S. et al. High fructose drives the serine synthesis pathway in acute myeloid leukemic cells. Cell Metab. 33, 145–159.e6 (2021).
Liu, H. et al. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res. 70, 6368–6376 (2010).
Goncalves, M. D. et al. High-fructose corn syrup enhances intestinal tumor growth in mice. Science 363, 1345–1349 (2019).
Bu, P. et al. Aldolase B-mediated fructose metabolism drives metabolic reprogramming of colon cancer liver metastasis. Cell Metab. 27, 1249–1262 (2018).
Chen, W. L. et al. GLUT5-mediated fructose utilization drives lung cancer growth by stimulating fatty acid synthesis and AMPK/mTORC1 signaling. JCI Insight 5, e131596 (2020).
Godoy, A. et al. Differential subcellular distribution of glucose transporters GLUT1–6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J. Cell. Physiol. 207, 614–627 (2006).
Liang, R. J. et al. GLUT5 (SLC2A5) enables fructose-mediated proliferation independent of ketohexokinase. Cancer Metab. 9, 12 (2021).
Douard, V. & Ferraris, R. P. The role of fructose transporters in diseases linked to excessive fructose intake. J. Physiol. 591, 401 (2013).
Francey, C. et al. The extra-splanchnic fructose escape after ingestion of a fructose–glucose drink: an exploratory study in healthy humans using a dual fructose isotope method. Clin. Nutr. ESPEN 29, 125–132 (2019).
Herman, M. A. & Birnbaum, M. J. Molecular aspects of fructose metabolism and metabolic disease. Cell Metab. 33, 2329–2354 (2021).
Jang, C. et al. The small intestine converts dietary fructose into glucose and organic acids. Cell Metab. 27, 351–361.e3 (2018).
Patton, E. E. et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249–254 (2005).
Febbraio, M. A. & Karin, M. ‘Sweet death’: fructose as a metabolic toxin that targets the gut-liver axis. Cell Metab. 33, 2316–2328 (2021).
Bray, G. A., Nielsen, S. J. & Popkin, B. M. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am. J. Clin. Nutr. 79, 537–580 (2004).
Taskinen, M. R., Packard, C. J. & Borén, J. Dietary fructose and the metabolic syndrome. Nutrients 11, 1987 (2019).
Sun, S. Z. & Empie, M. W. Fructose metabolism in humans—what isotopic tracer studies tell us. Nutr. Metab. 9, 89 (2012).
Chong, M. F. F., Fielding, B. A. & Frayn, K. N. Mechanisms for the acute effect of fructose on postprandial lipemia. Am. J. Clin. Nutr. 85, 1511–1520 (2007).
Diggle, C. P. et al. Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme. J. Histochem. Cytochem. 57, 763–774 (2009).
Ishimoto, T. et al. Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice. Proc. Natl Acad. Sci. USA 109, 4320–4325 (2012).
Mirtschink, P. et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature 522, 444–449 (2015).
Asipu, A., Hayward, B. E., O’Reilly, J. & Bonthron, D. T. Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria. Diabetes 52, 2426–2432 (2003).
Park, T. J. et al. Fructose-driven glycolysis supports anoxia resistance in the naked mole-rat. Science 356, 307–311 (2017).
Futatsugi, K. et al. Discovery of PF-06835919: a potent inhibitor of ketohexokinase (khk) for the treatment of metabolic disorders driven by the overconsumption of fructose. J. Med. Chem. 63, 13546–13560 (2020).
Sekas, G., Patton, G. M., Lincoln, E. C. & Robins, S. J. Origin of plasma lysophosphatidylcholine: Evidence for direct hepatic secretion in the rat. J. Lab. Clin. Med. 105, 185–189 (1985).
Graham, A., Zammit, V. A. & Brindley, D. N. Fatty acid specificity for the synthesis of triacylglycerol and phosphatidylcholine and for the secretion of very-low-density lipoproteins and lysophosphatidylcholine by cultures of rat hepatocytes. Biochem. J. 249, 727–733 (1988).
Baisted, D. J., Robinson, B. S. & Vancet, D. E. Albumin stimulates the release of lysophosphatidylcholine from cultured rat hepatocytes. Biochem. J. 253, 693–701 (1988).
Graham, A. et al. Factors regulating the secretion of lysophosphatidylcholine by rat hepatocytes compared with the synthesis and secretion of phosphatidylcholine and triacylglycerol Effects of albumin, cycloheximide, verapamil, EGTA and chlorpromazine. Biochem. J. 253, 687–692 (1988).
Ojala, P. J., Hirvonen, T. E., Hermansson, M., Somerharju, P. & Parkkinen, J. Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils. J. Leukoc. Biol. 82, 1501–1509 (2007).
Law, S. H. et al. An updated review of lysophosphatidylcholine metabolism in human diseases. Int. J. Mol. Sci. 20, 1149 (2019).
Gao, F., Chen, J., Zhang, T. & Liu, N. LPCAT1 functions as an oncogene in cervical cancer through mediating JAK2/STAT3 signaling. Exp. Cell. Res. 421, 113360 (2022).
Bi, J. et al. Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling. Cell Metab. 30, 525–538 (2019).
Mansilla, F. et al. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer. J. Mol. Med. 87, 85 (2009).
Tee, S. S. et al. Ketohexokinase-mediated fructose metabolism is lost in hepatocellular carcinoma and can be leveraged for metabolic imaging. Sci. Adv. 8, 7985 (2022).
Hwa, J. S. et al. The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma. Proteomics 6, 1077–1084 (2006).
David Wang, D. et al. Effect of fructose on postprandial triglycerides: a systematic review and meta-analysis of controlled feeding trials. Atherosclerosis 232, 125–133 (2014).
Jang, C. et al. The small intestine shields the liver from fructose-induced steatosis. Nat. Metab. 2, 586–593 (2020).
Gonzalez-Granda, A., Damms-Machado, A., Basrai, M. & Bischoff, S. C. Changes in plasma acylcarnitine and lysophosphatidylcholine levels following a high-fructose diet: a targeted metabolomics study in healthy women. Nutrients 10, 1254 (2018).
Kuliszkiewicz-Janus, M., Tuz, M. A. & Baczyński, S. Application of 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia. Biochim. Biophys. Acta 1737, 11–15 (2005).
Zhao, Z. et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J. Clin. Oncol. 25, 2696–2701 (2007).
Qiu, Y. et al. Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. Int. J. Mol. Sci. 14, 8047–8061 (2013).
Süllentrop, F. et al. 31P NMR spectroscopy of blood plasma: Determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed. 15, 60–68 (2002).
Yao, C. H. et al. Exogenous fatty acids are the preferred source of membrane lipids in proliferating fibroblasts. Cell Chem. Biol. 23, 483–493 (2016).
Corn, K. C., Windham, M. A. & Rafat, M. Lipids in the tumor microenvironment: from cancer progression to treatment. Prog. Lipid Res. 80, 101055 (2020).
Kamphorst, J. J. et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl Acad. Sci. USA 110, 8882–8887 (2013).
Sullivan, M. R. et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife 8, e44235 (2019).
Kaufman, C. K. et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science 351, aad2197 (2016).
Naser, F. J. et al. Isotope tracing in adult zebrafish reveals alanine cycling between melanoma and liver. Cell Metab. 33, 1493–1504 (2021).
Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002).
Madeira, F. et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 47, W636–W641 (2019).
Leinonen, R., Sugawara, H. & Shumway, M. The sequence read archive. Nucleic Acids Res. 39, D19–D21 (2011).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562–578 (2012).
Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).
Souroullas, G. P. et al. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat. Med. 22, 632–640 (2016). 2016 226.
Levi, J. et al. Fluorescent fructose derivatives for imaging breast cancer cells. Bioconjug. Chem. 18, 628–634 (2007).
McCommis, K. S. et al. Loss of mitochondrial pyruvate carrier 2 in liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling. Cell Metab. 22, 682–694 (2015).
Heilmann, S. et al. A quantitative system for studying metastasis using transparent zebrafish. Cancer Res. 75, 4272–4282 (2015).
Sindelar, M. et al. Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity. Cell Rep. Med. 2, 100369 (2021).
Spalding, J. L., Naser, F. J., Mahieu, N. G., Johnson, S. L. & Patti, G. J. Trace phosphate improves ZIC-pHILIC peak shape, sensitivity, and coverage for untargeted metabolomics. J. Proteome Res. 17, 3537–3546 (2018).
Sumner, L. W. et al. Proposed minimum reporting standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 3, 211 (2007).
Mahieu, N. G., Genenbacher, J. L. & Patti, G. J. A roadmap for the XCMS family of software solutions in metabolomics. Curr. Opin. Chem. Biol. 30, 87–93 (2016).
Koelmel, J. P. et al. Lipid annotator: towards accurate annotation in non-targeted liquid chromatography high-resolution tandem mass spectrometry (LC-HRMS/MS) lipidomics using a rapid and user-friendly software. Metabolites 10, 101 (2020).
Adams, K. J. et al. Skyline for small molecules: a unifying software package for quantitative metabolomics. J. Proteome Res. 19, 1447–1458 (2020).
Pang, Z. et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 49, W388–W396 (2021).
Schwaiger-Haber, M. et al. Using mass spectrometry imaging to map fluxes quantitatively in the tumor ecosystem. Nat. Commun. 14, 2876 (2023).
Buescher, J. M. et al. A roadmap for interpreting 13C metabolite labeling patterns from cells. Curr. Opin. Biotechnol. 34, 189–201 (2015).
Llufrio, E. M., Cho, K. & Patti, G. J. Systems-level analysis of isotopic labeling in untargeted metabolomic data by X13CMS. Nat. Protoc. 14, 1970–1990 (2019).
Chen, P. H. et al. Metabolic diversity in human non-small cell lung cancer cells. Mol. Cell 76, 838–851 (2019).
Burk, R. D. et al. Integrated genomic and molecular characterization of cervical cancer. Nature 543, 378–384 (2017).
Liao, Y., Smyth, G. K. & Shi, W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511–515 (2010).
[ad_2]
Source link
